Regression of left ventricular hypertrophy; What are appropriate therapeutic objectives?

British Journal of Clinical Pharmacology

Volumn 47, Issue 2, 1999, Pages 125-130

  Sheridan, Desmond J ^a,b   Kingsbury, M P ^a   Flores, N A ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Cardiac hypertrophy; Coronary haemodynamics; Electrophysiology; Regression

Indexed keywords

ANTIHYPERTENSIVE THERAPY; ECHOCARDIOGRAPHY; HEART ELECTROPHYSIOLOGY; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEMODYNAMICS; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE;

EID: 0033035644     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00871.x     Document Type: Review

References (84)

1. Savage DD, Garrison RJ, Kannel WB, et al. The spectrum of left ventricular hypertrophy in a general population sample: The Framingham Study. Circulation 1987; 75 (Suppl 1): 26.
2. Pichard AD, Gorlin R, Smith H, et al. Coronary flow studies in patients with left ventricular hypertrophy of the hypertensive type. Evidence for an impaired coronary vascular reserve. Am J Cardiol 1981; 47: 547-553.
3. Opherk D, Mall G, Zebe H, et al. Reduction of coronary reserve: a mechanism for angina pectoris in patients with arterial hypertension and normal coronary arteries. Circulation 1984; 69: 1-7.
4. Marcus ML, Doty DB, Hiratzka LF, et al. A mechanism for angina pectoris in patients with aortic stenosis and normal coronary arteries. N Engl J Med 1982; 307: 1362-1367.
5. Kannel WB. Prevalence and natural history of electrocardiographic left ventricular hypertrophy. Am J Med 1983; 75 (Suppl 3A): 4-11.
6. Kannel WB. Left ventricular hypertrophy as a risk factor for arterial hypertension. Eur Heart J 1992; 13 (Suppl D): 82-88.
7. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med 1990; 322: 1561-1566.
8. Levy D, Anderson KM, Savage DD, et al. Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham heart study. Am J Cardiol 1987; 60: 560-565.
9. Cooper RS, Simmons BE, Castaner A, et al. Left ventricular hypertrophy is associated with worse survival independent of ventricular function and number of coronary arteries severely narrowed. Am J Cardiol 1990; 65: 441-445.
10. Gordon T, Kannel WB. Premature mortality from coronary heart disease. The Framingham study. JAMA 1971; 215: 1617-1625.
11. Jeremy RW, Fletcher PJ, Thompson J. Coronary pressure-flow relations in hypertensive left ventricular hypertrophy. Comparison of intact autoregulation with physiological and pharmacological vasodilatation in the dog. Circ Res 1989; 65: 224-236.
12. Pichard AD, Smith H, Holt J. Coronary vascular reserve in left ventricular hypertrophy secondary to chronic aortic regurgitation. Am J Cardiol 1983; 51: 315-320.
13. Shimamatsu M, Toshima H. Impaired coronary vasodilatory capacity after dipyridamole administration in hypertrophic cardiomyopathy. Jpn Heart J 1987; 28: 387-401.
14. Isoyama S, Ito I, Kurcha M, et al. Complete reversibility of physiological coronary vascular abnormalities in hypertrophied hearts produced by pressure overload in the rat. J Clin Invest 1989; 84: 288-294.
15. O'Gorman DJ, Thomas P, Turner MA, et al. Investigation of impaired coronary vasodilator reserve in the guinea-pig heart with pressure induced hypertrophy. Eur Heart J 1992; 13: 697-703.
16. O'Gorman DJ, Sheridan DJ. Abnormalities of the coronary circulation associated with left ventricular hypertrophy. Clin Sci 1991; 81: 703-713.
17. Breisch E, White FC, Nimmo LE, et al. Cardiac vasculature and flow during pressure overload hypertrophy. Am J Physiol 1986; 251: H1031-H1037.
18. Vatner SF, Shannon R, Hittinger L. Reduced subendocardial coronary reserve. A potential mechanism for impaired diastolic function in the hypertrophied and failing heart. Circulation 1990; 81 (Suppl III), III-8-III-14.
19. Rembert JC, Kleinman LH, Fedor JM. Myocardial blood flow distribution in concentric LV hypertrophy. J Clin Invest 1978; 62: 379-386.
20. Radvan J, O'Gorman D, Turner MA, et al. Morphological and numerical changes in resistance vessels in pressure overload left ventricular hypertrophy (LVH). Br Heart J 1995; 73: P32.
21. Marcus ML, Harrison DG, Chilian WM, et al. Alterations in the coronary circulation in hypertrophied ventricles. Circulation 1987; 75 (Suppl 1): 1-19.
22. Wangler RD, Peters KG, Marcus M, et al. Effects of duration and severity of arterial hypertension and cardiac hypertrophy on coronary vasodilator reserve. Circ Res 1982; 51: 1-10.
23. Tomanek RJ, Schalk KA, Marcus ML, et al. Coronary angiogenesis during long-term hypertension and left ventricular hypertrophy in dogs. Circ Res 1989; 65: 352-359.
24. Malik AB, Abe T, O'Kane H, et al. Cardiac function, coronary flow and oxygen consumption in stable left ventricular hypertrophy. Am J Physiol 1973; 225: 186-191.
25. Hittinger L, Shannon RP, Bishop SP, et al. Sub endomyocardial exhaustion of blood flow reserve and increased fibrosis in conscious dogs with heart failure. Circ Res 1989; 65: 971-980.
26. McAinsh AM, Turner MA, O'Hare D, et al. Cardiac hypertrophy impairs recovery from ischaemia because there is a reduced reactive hyperaemic response. Cardiovasc Res 1995; 30: 113-121.
27. Messerlie FH, Venture HO, Elizardi DJ, et al. Hypertension and sudden death: increased ventricular ectopic activity in left ventricular hypertrophy. Am J Med 1984; 77: 18-22.
28. McLenachan JM, Henderson E, Morris KI, et al. Ventricular arrhythmias in paitents with hypertensive left ventricular hypertrophy. N Engl J Med 1987; 317: 787-792.
29. Ghali JK, Kadakia S, Cooper RS, et al. Impact of left ventricular hypertrophy on ventricular arrhythmias in the absence of coronary artery disease. J Am Coll Cardiol 1991; 17: 1277-1282.
30. Hart G. Cellular electrophysiology in cardiac hypertrophy and failure. Cardiovasc Res 1994; 28: 933-946.
31. Winterton SJ, Turner MA, O'Gorman DJ, et al. Hypertrophy causes delayed conduction in human and guinea pig myocardium: accentuation during ischaemic perfusion. Cardiovasc Res 1994; 28: 47-54.
32. Cooklin M, Wallis WRJ, Sheridan DJ, et al. Changes to cell-to-cell electrical coupling associated with left ventricular hypertrophy. Circ Res 1997; 80: 765-771.
33. + buffering capacity in guinea-pigs with left ventricular hypertrophy induced by constriction of the thoracic aorta. Exp Physiol 1997; 82: 227-230.
34. White RL, Spray DC, Campos De Carvalho AC, et al. Some electrical and pharmacological properties of gap junctions between adult ventricular myocytes. Am J Physiol 1985; 249: C447-C455.
35. Davey PP, Bateman J, Mulligan IP, et al. QT Interval dispersion in chronic heart failure and left ventricular hypertrophy: relation to autonomic nervous system and holter tape abnormalities. Br Heart J 1994; 71: 268-273.
36. Mayet J, Shahi M, McGrath K, et al. Left ventricular hypertrophy and QT dispersion in hypertension. Hypertension 1996; 28: 791-796.
37. Multiple risk factor intervention trial research group. Multiple risk factor intervention trial. Risk factor changes and mortality results. JAMA 1982; 248: 1465-1477.
38. Collins R, Petro R, MacMahon S. Blood pressure, stroke and coronary heart disease. Part 2 Short term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
39. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50: 272-298.
40. Hartford M, Wendelhag L, Berglund G, et al. Cardiovascular and renal effects of long-term antihypertensive treatment. JAMA 1988; 259: 2553-2557.
41. Dunn FG, Ventura HO, Messerlie EH, et al. Time course of regression of left ventricular hypertrophy in hypertensive patients treated with atenolol. Circulation 1987; 76: 254-258.
42. Ram CV, Gonzalez D, Kulkarni P. Regression of left ventricular hypertrophy in hypertension. Effects of prazosin therapy. Am J Med 1989; 86: 66-69.
43. Schmieder RRE, Messerli FH, Garavaglia GE, et al. Cardiovascular effects of verapamil in patients with essential hypertension. Circulation 1987; 75: 1030-1036.
44. Grossman E, Oren S, Garavaglia GE, et al. Systemic and regional hemodynamic and humoral effects of nitrendipine in essential hypertension. Circulation 1988; 78: 1394-1400.
45. Shahi M, Thom S, Poulter N, et al. Regression of hypertensive left ventricular hypertrophy and left ventricular diastolic function. Lancet 1990; 336: 458-461.
46. Dunn FG, Oigman W, Ventura HO, et al. Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. Am J Cardiol 1984; 53: 105-108.
47. Ferrara LA, De Simone G, Mancini M, et al. Changes in left ventricular mass during a double blind study with chlorthalidone and slow release nifedipine. Eur J Clin Pharmacol 1984; 27: 525-528.
48. Liebson PH, Greg A, Grandits MS, et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the treatment of mild hypertension study (TOMHS). Circulation 1995; 91: 698-706.
49. Villari B, Hess OM, Meier C, et al. Regression of coronary artery dimensions after successful aortic valve replacement. Circulation 1992; 85: 972-978.
50. Waszyrowski T, Kasprzak JD, Krzemiska-Pakua M, et al. Regression of left ventricular dilatation and hypertrophy after aortic valve replacement. Int J Cardiol 1996; 57: 217-225.
51. Dahlof B, Pennert K, Hansson L. Reversal of ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. Am J Hypertension 1992: 5: 95-110.
52. Cruickshank J, Lewes J, Moore EV, et al. Reversibility of left ventricular hypertrophy by different types of antihypertensive therapy. J Hum Hypertension 1992; 6: 85-90.
53. Schmeider RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind trials. JAMA 1996; 275: 1507-1513.
54. Gottdiener JS, Reda DJ, Massie BM, et al. for the BA Cooperative Study Group on Antihypertensive Agents. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension. Circulation 1997; 95: 2007-2014.
55. Devereux RB. Do antihypertensive drugs differ in their ability to regress left ventricular hypertrophy? Circulation 1997; 95: 1983-1985.
56. Gosse P, Guez D, Gueret P, et al. Centralized echocardiogram quality control in a multicenter study of regression of left ventricular hypertrophy in hypertension. J Hypertension 1998; 16: 531-535.
57. Devereux RB, Dahlof B, Levy D, et al. Comparison of enalapril vs nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial). Am J Cardiol 1996; 78: 61-65.
58. Dahlof B, Devereux RB, de Faire U, et al. for the LIFE Study Group. Losartan Intervention For End-point reduction in hypertension (the LIFE study). Am J Hypertension 1996; 9: 26A. Abstract.
59. Levy D, Salomon M, D'Argostino RB, et al. Prognostic implications of baseline electrocardiographic features and their serial change in subjects with electrocardiographic left ventricular hypertrophy. Circulation 1994; 90: 1786-1793.
60. Yurenev AP, Dyakonova HG, Novilov ID, et al. Management of essential hypertension in patients with different degrees of left ventricular hypertrophy: multi-center trial. Am J Hypertension 1992; 5: 1825-1895.
61. Villiari B, Hess OM, Meier C, et al. Regression of coronary artery dimensions after successful aortic valve replacement. Circulation 1992; 85: 972-978.
62. Eberli FR, Ritter M, Schwitter J, et al. Coronary reserve in patients with aortic valve disease before and after successful aortic valve replacement. Eur Heart J 1991; 12: 127-38.
63. Parodi O, Neglia D, Palombo C, et al. Comparative effects of enalapril and verapamil on myocardial blood flow in systemic hypertension. Circulation 1997; 96: 864-873.
64. Schulman DS, Flores AR, Tugoen J, er al. Antihypertensive treatment in hypertensive patients with normal left ventricular mass is associated with left ventricular remodeling and improved diastolic function. Am J Cardiol 1996; 78: 56-60.
65. Shahi M, Thom S, Poulter N, et al. The effects of blood pressure reduction on abnormal left ventricular diastolic function in hypertensive patients. Eur Heart J 1991; 12: 974-979.
66. Okabe M, Kawamura K, Kimpara T, et al. Electron microscopic study on regression of cardiac hypertrophy in spontaneously hypertensive rats. Med Electron Microscopy 1994; 27: 239-242.
67. Chevalier B, Callens-El-Amrani F, Heymes C, et al. The molecular basis of regression of cardiac hypertrophy. Am J Cardiol 1994; 73: 10c-17c.
68. Kohya T, Yokoshiki H, Tohse N, et al. Regression of left ventricular hypertrophy prevents ischaemia-induced lethal arrhythmias: beneficial effect of angiotensin II blockade. Circ Res 1995; 76: 892-899.
69. Okamoto K, Abe M, Hanada T. Effect of regression of cardiac hypertrophy on ischaemic myocardial damage in spontaneously hypertensive rats. Jap Circ J 1993; 57: 147-160.
70. Brilla CG, Janicki JS, Weber KT. Impaired diastolic function and coronary reserve in genetic hypertension. Role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res 1991; 69: 107-115.
71. Vogt M, Motz W, Stauer BE. Long-term treatment in arterial hypertension for protecting myocardium. Basic Res Cardiol 1991; 86: 223-233.
72. Vassalli G, Hess OH, Krogman ON, et al. Coronary artery size in mitral regurgitation and its regression after mitral valve surgery. Am Heart J 1993; 126: 1091-1098.
73. Motz W, Vogt M, Scheler S, et al. Improvement of coronary reserve after regression of hypertrophy resulting from blood pressure reducing treatment with bisoprolol, a beta-receptor blocker. Deutsche Med Wochenschrift 1993; 118: 535-540.
74. Raman VJ, Lee YA, Lindpainter K. The cardiac renin-angiotensin-aldosterone system and hypertensive cardiac hypertrophy. Am J Cardiol 1995; 76: 18D-13D.
75. Schunkert H, Dzau, VJ, Tang SS, et al. Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy: effects on coronary resistance, contractility, and relaxation. J Clin Invest 1990; 86: 1913-1920.
76. Baker KM, Cherin MI, Wixon SK, et al. Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol 1990; 259: H324-H332.
77. Weber KT, Brilla CG. Pathologic hypertrophy and cardiac interstitium: fibrosis and the renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-1856.
78. Yamazaki T, Komuro I, Kudoh S, et al. Angiotensin II partly mediates mechanical stress-induced cardiachypertrophy. Circ Res 1995; 77: 258-265.
79. Paquet JL, Bandomin-Legros M, Brunelle G, et al. Angiotensin II-induced proliferation of aortic myocytes in spontaneously hypertensive rats. J Hypertension 1990; 8: 565-572.
80. Morishita R, Gibbons GH, Ellison KE, et al. Evidence for direct local effect of angiotensin II in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme. J Clin Invest 1995; 95: 978-984.
81. Timmermans PBMWM, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonist. Pharmacol Rev 1993; 45: 205-251.
82. 1 receptor subtype. Circ Res 1993; 73: 413-423.
83. 2 receptors in the developing rat fetus. J Clin Invest 1991; 88: 921-933.
84. Brilla CG, Zhou G, Matsubara L, et al. Collagen metabolism in cultured adult rat cardiac fibroblast: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994; 26: 809-820.